Where trigeminal neuralgia treatment is heading

Trigeminal neuralgia causes sudden, electric-shock face pain. Carbamazepine works for most at first; when it fails or causes side effects, decompression surgery, radiosurgery or needle procedures follow. Research is testing new pills, flare-up rescue drugs and gene therapy.

• 46studies open or running
• 1phase 3 trial
• 490papers published this year
• 9NIH-funded projects

1. Now

   Nov 2026

   IV rescue for severe flare-upsHappened 90.9% relieved in 2 hours

   In a small trial, IV fosphenytoin halved pain within 2 hours for 90.9% vs 40.0% on placebo.

   90.9%: had at least half their pain relieved at 2 hours, vs 40.0% with placebo.

   • IV fosphenytoin trial

   Radiosurgery lasts longer than needle proceduresHappened 30% fewer relapses

   Relapse risk was about 30% lower than with rhizotomy, though relief came slower.

   30%: lower risk of pain coming back after radiosurgery.

   • Radiosurgery vs rhizotomy review

   Repeat procedures help manyHappened 49.6% pain-free at 3 yrs

   49.6% stayed pain-free about 3 years after a second procedure.

   49.6%: pain-free about 3 years after a repeat procedure.

   • Repeat surgery review

2. 6 months

   by May 2027

   Botox as a non-surgical optionPossible

   Pooled studies show less pain and fewer attacks; larger trials are needed before routine use.

   • Botox review

3. 12 months

   by Nov 2027

   First new pill in decades reads outLikely

   A 166-person phase 3 trial of basimglurant, which dampens glutamate signals, finishes February 2027.

   • Basimglurant phase 3

4. 3 years

   by late 2029

   Radiosurgery earlier, before drugs failPossible

   An Alberta trial tests Gamma Knife soon after diagnosis rather than as a last resort.

   • Early Gamma Knife trial
   • Radiosurgery vs rhizotomy review

   Gene therapy first-in-human dataLong shot

   Kriya is testing RP-008, a gene therapy switched on by the quit-smoking pill varenicline.

   • RP-008 trial

5. 5 years

   by late 2031

   Gene therapy aimed at pain nervesLong shot

   NIH funds a Brigham and Women's project and a SereNeuro gene therapy for facial pain nerves.

   • Brigham gene delivery project
   • SereNeuro SN102 project

The research paths

Borrowed from other conditions

Open to join now

• Newly diagnosed TN, Canada

  Early Gamma Knife radiosurgery

  Phase 2 · 2 sites

  Locations and eligibility →

• Drug-resistant TN

  RP-008 gene therapy with varenicline

  Phase 2 · 1 site

  Locations and eligibility →

• TN, Stanford

  Liposomal bupivacaine injection

  Phase 2 · 1 site

  Locations and eligibility →

See every recruiting Trigeminal neuralgia trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

Knowledge on the way

Not treatments yet: detection, causes and how care is delivered. Mostly NIH-funded.

• AreaQuestionFunded throughNews likely
• Causes How trigeminal nerve injury causes lasting painUniversity of Pittsburgh · NIH Funded through Jun 2027 News likely 2027–2028
• Gene therapy Delivering genes only to pain-sensing face nervesBrigham and Women's Hospital · NIH Funded through May 2031 News likely 2029+

What just happened

Standard treatment today

• First treatmentCarbamazepine or oxcarbazepine pills.
• Pills fail or not toleratedMicrovascular decompression surgery if fit; otherwise radiosurgery or a needle rhizotomy.
• Severe flare-upHospital care; IV drugs such as fosphenytoin are being studied as rescue.

See Trigeminal neuralgia trials recruiting now →